Zortress

Zortress is a brand name of everolimus, approved by the FDA in the following formulation(s):

ZORTRESS (everolimus - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: April 20, 2010
  
  Strength(s): 0.25MG, 0.5MG, 0.75MG ^[RLD]

Has a generic version of Zortress been approved?

No. There is currently no therapeutically equivalent version of Zortress available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zortress. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
  Patent 5,665,772
  Issued: September 9, 1997
  Inventor(s): Cottens; Sylvain & Sedrani; Richard
  Assignee(s): Sandoz Ltd.
  Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
  
  Patent expiration dates:
  
  
  • September 9, 2019
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical compositions comprising rafamycin coprecipitates
  Patent 6,004,973
  Issued: December 21, 1999
  Inventor(s): Guitard; Patrice & Haeberlin; Barbara & Link; Rainer & Richter; Friedrich
  Assignee(s): Novartis AG
  Disclosed are pharmaceutical compositions containing solid dispersions in the form of co-precipitates, which solid dispersions contain rapamycin and a carrier medium, and methods of treatment utilizing such pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • July 12, 2016
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
  Patent 6,239,124
  Issued: May 29, 2001
  Inventor(s): Zenke; Gerhard & Schuurman; Hendrik & Haeberlin; Barbara & Meinzer; Armin
  Assignee(s): Novartis AG
  A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
  
  Patent expiration dates:
  
  
  • August 11, 2017
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
  
  



• 
  O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
  Patent 6,440,990
  Issued: August 27, 2002
  Inventor(s): Sylvain; Cottens & Richard; Sedrani
  Assignee(s): Novartis AG
  Novel derivatives of rapamycin, particularly 9-deoxo-rapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,O-disubstituted rapamycins. are found to have pharmaceutical utility, particularly as immunosuppressants.
  
  Patent expiration dates:
  
  
  • September 24, 2013
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
  Patent 6,455,518
  Issued: September 24, 2002
  Inventor(s): Gerhard; Zenke & Hendrik; Schuurman & Barbara; Haeberlin & Armin; Meinzer
  Assignee(s): Novartis AG
  A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
  
  Patent expiration dates:
  
  
  • July 29, 2017
    
    ✓ 
    Patent use: PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 20, 2013 - NEW PRODUCT
  
  
  • March 30, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Zortress Consumer Information (Drugs.com)
• Zortress Consumer Information (Wolters Kluwer)
• Zortress Consumer Information (Cerner Multum)
• Zortress Advanced Consumer Information (Micromedex)
• Everolimus Consumer Information (Wolters Kluwer)
• Everolimus Consumer Information (Cerner Multum)
• Everolimus Advanced Consumer Information (Micromedex)
• Everolimus AHFS DI Monographs (ASHP)